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Altering the balance between energy intake and ex-
penditure is a potential strategy for treating obesity
andmetabolic syndrome. Nonetheless, despite years
of progress in identifying diverse molecular targets,
biological-based therapies are limited. Here we
demonstrate that heat shock factor 1 (HSF1) re-
gulates energy expenditure through activation of a
PGC1a-dependent metabolic program in adipose
tissues and muscle. Genetic modulation of HSF1
levels altered white fat remodeling and thermogene-
sis, and pharmacological activation of HSF1 via
celastrol was associated with enhanced energy
expenditure, increased mitochondrial function in fat
and muscle and protection against obesity, insulin
resistance, and hepatic steatosis during high-fat
diet regimens. The beneficial metabolic changes eli-
cited by celastrol were abrogated in HSF1 knockout
mice. Overall, our findings identify the temperature
sensor HSF1 as a regulator of energy metabolism
and demonstrate that augmenting HSF1 via celastrol
represents a possible therapeutic strategy to treat
obesity and its myriad metabolic consequences.
INTRODUCTION
The accumulation of excessive fat tissue, the result of an
imbalance between energy input and its output, leads to
obesity, diabetes, cardiovascular disease, and hepatosteatosis,
which together represent the leading causes of adult morbidity
andmortality worldwide. Themain site of energy storage is white
adipose tissue (Farmer, 2008; Mueller, 2014; Gesta et al., 2007),
while brown fat is principally involved in energy expenditure via
thermogenesis, achieved through the dissipation of chemical en-
ergy via the activity of Uncoupling Protein 1 (UCP1), a mitochon-Celldrial protein uncoupling respiration from ATP synthesis. For a
considerable period of time this rigid framework defined our
view of how energy balance was controlled. Recently, this view-
point has been altered to incorporate the observation that adult
humans containmeasurable amounts of brown fat (Cypess et al.,
2009; Skarulis et al., 2010; Ouellet et al., 2012). Recently a new
cell type of smooth muscle origin (Long et al., 2014), called brite
or beige, has been shown to be inducible upon cold or hormonal
stimuli, causing brown remodeling of white fat, expressing UCP1
and contributing to energy expenditure (Nedergaard and Can-
non, 2014; Wu et al., 2012; Sharp et al., 2012). In addition, beige
cells directly sense temperature changes, suggesting a cell-
autonomous mechanism to activate thermogenesis in brite/
beige fat depots (Ye et al., 2013). This newly discovered ‘‘plas-
ticity’’ of adipocytes has intensified efforts to identify novel
methods to treat obesity and insulin resistance by increasing
browning and peripheral energy expenditure (Boss and Farmer,
2012; Cypess and Kahn, 2010).
Mitochondrial dysfunction has been shown to be associated
with the development of obesity and insulin resistance (Bournat
and Brown, 2010; Patti and Corvera, 2010). The peroxisome pro-
liferator-activated receptor g coactivator-1a (PGC-1a) is a cen-
tral transcriptional regulator of mitochondrial and peroxisomal
remodeling and biogenesis (Wu et al., 1999; Bagattin et al.,
2010). Genetic analysis of PGC1a requirement in vivo via gener-
ation of total and conditional knockout mice has revealed its
involvement in thermogenesis, mitochondrial gene expression
(Lin et al., 2004; Leone et al., 2005), and browning of white fat
tissues (Kleiner et al., 2012). In addition to fat, skeletal muscle
represents a critical metabolic organ in energy homeostasis. It
has been shown that PGC1a controls mitochondrial and oxida-
tive fiber conversion gene programs in muscle to increase en-
ergy expenditure to match metabolic needs (Handschin and
Spiegelman, 2006; Lagouge et al., 2006). Interestingly, mice
with neuronal inactivation of PGC1a show hyperactivity and
resistance to diet-induced obesity but normal adaptive response
to cold exposure, suggesting critical metabolic roles of PGC1a in
both central and peripheral tissues (Ma et al., 2010). PGC1a is
tightly regulated by a number of signal transduction effectors,Metabolism 22, 695–708, October 6, 2015 ª2015 Elsevier Inc. 695
such as AMPK, SIRT1, mTOR, and GCN5, which orchestrate
posttranslational modifications that either enhance or repress
PGC1a activity in brown adipose tissue, muscle, and liver (Canto´
and Auwerx, 2009; Cunningham et al., 2007; Lerin et al., 2006)
and transcriptionally induced by thermal, oxidative, and me-
chanical challenges (St-Pierre et al., 2006; Handschin et al.,
2007; Egan et al., 2010).
In response to stress, activated heat shock factor 1 (HSF1) ex-
erts pleotropic effects (Anckar and Sistonen, 2011). In addition to
the classic induction by heat shock, HSF1 is also activated by
cold temperatures (Cullen and Sarge, 1997) and plays a role
in circadian changes in body temperature through clock gene
regulation (Reinke et al., 2008). To date, there has been no
mechanistic link between HSF1 and PGC1a, although a recent
genome-wide analysis of PGC1a binding sites in transformed
hepatocytes raised the possibility of potential occupancy of
PGC1a at heat shock response elements in liver cells (Charos
et al., 2012). HSF1’s most explored function to date has been
the regulation of the expression of genes encoding for chap-
erone proteins to protect cells against temperature changes,
oxidative stress, and hypoxia. In response to these stimuli,
HSF1 is activated via the dissociation of HSP90, HSP70, and
HSP40, and, upon multimerization and posttranslational modifi-
cations (Xu et al., 2012), HSF1 binds to DNA to induce its down-
stream gene targets through three types of heat shock elements
(HSEs). These elements are defined depending on the organiza-
tion of their GAA/TTC core domains as classic, gap type, or TTC
rich (Eastmond and Nelson, 2006; Guo et al., 2008). HSF1 activ-
ity can be modulated by a variety of compounds with different
chemical structures (Fujikake et al., 2008). One such agent is ce-
lastrol, a compound that is known to be capable of inducing
classic HSF1 heat shock target genes (Westerheide et al.,
2004). Despite the number of reports on the biological functions
of HSF1, no studies have yet specifically evaluated the effects of
modulation of HSF1 levels and activity on energy metabolism.
Here, we directly linked the activation of HSF1 to the induction
of PGC1a gene expression and to that of PGC1a downstream
programs, thereby defining a critical regulatory axis between
these two transcription factors. We show that activation of
HSF1 by the natural compound celastrol has profound effects
in vitro and in vivo in mice on high-fat diet (HFD) by increasing
their energy expenditure, inducing browning of iWAT and brown
fat programs in BAT, and activatingmitochondrial gene targets in
muscle. Our work identifies HSF1 as an important metabolic
regulator in mesenchymal cells and tissues and proposes a
potent pathway that can be activated for the treatment of obesity
and related metabolic disorders.
RESULTS
HSF1 Regulates PGC1a Levels and Brown and
Mitochondrial Gene Programs In Vitro
Given the established role of PGC1a in browning of white fat
tissue (Wu et al., 1999, Kleiner et al., 2012) and in increasing
mitochondrial function in muscle (Lin et al., 2002), we aimed to
identify upstream regulators of PGC1a and used the transcrip-
tional activation of PGC1a as a readout to characterize novel
regulators of energy expenditure. By performing an in silico
screen of transcription factor binding elements in the regulatory696 Cell Metabolism 22, 695–708, October 6, 2015 ª2015 Elsevier Inregion upstream of the PGC1a start site, we identified multiple
repeats exhibiting the characteristic core motif 50-nTTCn-30
(see Figure S1A available online), previously described as a non-
canonical TTC-rich binding site for the heat shock transcription
factor HSF1 (Eastmond and Nelson, 2006; Guo et al., 2008).
Electromobility shift analysis and luciferase reporter assays
confirmed HSF1’s binding at nucleotides 2,369 to 2,346 in
the mouse PGC1a promoter (Figures 1A and S1B). To determine
the physiological relevance of this finding, we performed chro-
matin immunoprecipitation (ChIP) assays and showed increased
HSF1 occupancy at this site, but not at control sites, in BAT and
iWAT of mice exposed to cold temperatures (Figures 1B and
S1C). Given the previously reported role of PGC1a in the poten-
tiation of its own expression (Handschin et al., 2003), we next
performed coimmunoprecipitation studies to assess the interac-
tion between PGC1a and HSF1 on the PGC1a promoter. Our
analysis revealed that HSF1 binds to PGC1a and that this inter-
action is enhanced by the addition of the HSF1 activator celastrol
(Figure 1C). Furthermore, ChIP and re-ChIP studies confirmed
that PGC1a and HSF1 co-occupy selectively the HSE in the
PGC1a promoter (Figures 1D, S1D, and S1E).
We next used the mesenchymal cell line 10T1/2, previously
shown to induce endogenous PGC1a levels in response to a
variety of stimuli (St-Pierre et al., 2006), to test the effects of
HSF1 modulation in vitro. Forced HSF1 expression increased
PGC1a mRNA levels, which were further elevated after the
addition of celastrol (Figure S1F). The ability of HSF1 to induce
PGC1a mRNA was also confirmed using additional activators
of HSF1 (Fujikake et al., 2008), such as the chemical compounds
17-allylamino-17-demethoxy-geldanamycin (17-AAG), geranyl-
geranylacetone (GAA), or radicicol (RA) and through classic
heat shock stimulation (Figure S1G). These results indicated
that PGC1a levels are indeed elevated as a result of HSF1 acti-
vation, rather than the consequence of nonspecific, off-target
effects of selected compounds. Analysis of isoform selectivity
revealed that PGC1a1 is the only PGC family member regulated
by HSF1 and that there are no compensatory changes in PGC1b
(Figure S1H). Further analysis of HSF1’s activation revealed
the elevation of brown fat selective markers, such as PRDM16
and UCP1, as well as mitochondrial and fatty acid metabolism
genes (Figures 1E and S1I–1L), but no induction of differentiation
genes (Figure S1M). The heat shock protein HSP70, an estab-
lished gene target of HSF1, served as a marker for the efficacy
of the activators used to elicit HSF1-mediated transcriptional
responses.
Given the presence of a HSE in the upstream regulatory regions
of the human PGC1a gene (Figure S1A), we tested the effects of
HSF1 activation in cells obtained from subcutaneous fat of obese
patients. Similarly to murine cells, brown-specific gene expres-
sion programs were increased by celastrol in differentiated stro-
mal-vascular fraction (SVF) cells obtained from obese subjects,
thereby confirming the role of HSF1 in the regulation of PGC1a
and brown fat and mitochondrial programs in human cells as
well (Figure S1N). Furthermore, ablation of HSF1 function via
HSF1 siRNA knockdown reduced the expression levels of
PGC1a and that of its target genes, further confirming that HSF1
regulates PGC1a and brown fat markers (Figures 1F and S1O).
Given that HSF1 binds to the PGC1a promoter after acute
cold exposure (Figure 1B) and the previously reported evidencec.
Figure 1. HSF1 Regulates PGC1a and
PGC1a-Dependent Gene Programs
(A) HSF1 overexpression and its activation by ce-
lastrol (CEL) in 10T1/2 cells induce a luciferase
wild-type PGC1a promoter reporter (PGC1a-luc),
but not a mutant reporter with a deletion of the
putative HSE site (PGC1a-luc del HSE).
(B) In vivo ChIP assay assessing HSF1 binding at
the putative HSE site in the PGC1a promoter or in
the b-globin promoter in BAT and iWAT of mice
exposed to room temperature or to cold for 2 hr.
(C) CoIP analysis of HSF1 and PGC1a interaction
in differentiated 10T1/2 cells with or without CEL
treatment.
(D) ChIP assay in 10T1/2 cells assessing HSF1 and
PGC1a occupancy at the putative HSE site in the
PGC1a promoter and at the b-globin promoter, in
the presence (+) or absence () of CEL.
(E) Regulation of PGC1a and brown fat gene levels
by CEL in differentiated 10T1/2 cells.
(F) Analysis of the levels of PGC1a mRNAs in
control and in HSF1 knockdown (Si-HSF1) differ-
entiated 10T1/2 cells treated with vehicle or CEL.
Data are presented as mean ± SEM from three
independent experiments and *p < 0.05, **p < 0.01
compared to control group.of fat cells’ intrinsic capability to sense cold temperatures, we
assessed the potential involvement of HSF1 in cell-autonomous
cold sensing. We exposed control or HSF1 siRNA expressing
cells to 31C, a temperature known to induce the expression of
UCP1 in isolated cells (Ye et al., 2013), and demonstrated that
while control cells responded to cooling by increasing PGC1a
and UCP1 levels, cells with HSF1 knockdown had a blunted in-
duction of these thermogenic factors (Figures S1P–S1R). These
data suggest a potential role for HSF1 in fat-cell-autonomous
temperature sensing and in eliciting thermogenic responses.
HSF1 Null Mice Have Impaired Energy Metabolism
Based on the observation that HSF1 regulates the expression of
brown fat markers andmitochondrial genes in vitro (Figure 1), we
next performed genetic analyses to determine whether modula-
tion of HSF1 levels in vivo would alter metabolism. Given that no
studies to date have assessed the impact of HSF1 on energy bal-
ance, we characterized the metabolic consequences of HSF1’s
ablation in mice. HSF1 null mice showed increased brown (BAT)
and inguinal fat depots (iWAT) (Figure 2A), enhanced lipid depo-
sition (Figure 2B), decreased levels of brown fat markers (Fig-
ure 2C), and reduced UCP1 staining and levels in iWAT (Figures
2D and 2E). These alterations were associated with decreased
total body oxygen consumption (Figure 2F), impaired cold resis-
tance (Figure 2G), and reduced levels of PGC1a and UCP1 in
brown and inguinal fat tissue of cold-exposed HSF1 null mice
(Figure 2H), with no concomitant changes in food intake nor in
locomotor activity (Figures S2A and S2B). The impaired geneCell Metabolism 22, 695–708expression and metabolic responses
observed in HSF1 null mice were recapit-
ulated in isolated cells obtained from BAT
and iWAT, showing reduced PGC1a and
UCP1 gene expression (Figure S2C)along with decreased oxygen consumption rates (OCRs) (Fig-
ure 2I), suggesting a cell-autonomous effect of HSF1’s deletion
on energetics. Taken together, these data demonstrate that
HSF1’s ablation in mice alters mitochondrial and brown fat
gene programs in brown and inguinal fat tissues and affects ther-
mogenic function and energy expenditure.
HSF1 Regulates White Fat Browning through PGC1a
Given the importance of inducible brown adipocytes in white fat
(Harms and Seale, 2013), we next asked if modulation of HSF1’s
levels specifically in white fat depots could recapitulate, at
least in part, the effects of HSF1’s deficiency on brown andwhite
fat observed in HSF1 null mice. Several methods have been
recently used to study tissue- and depot-selective effects of
gain or loss of function of specific genes circumventing the
generation of conditional knockout mice (Kraus et al., 2014;
Whittle et al., 2012; Qian et al., 2013). We took advantage of
adenoviral delivery techniques we previously used to efficiently
up- or downregulate genes of interest selectively in inguinal fat
tissues of C57BL/6J mice (Ma et al., 2014). HSF1 depletion in
iWAT was associated with increased size of subcutaneous
fat cells, decreased UCP1 staining, and reduced levels of brown
fat markers (Figures 3A–3D). Conversely, increased HSF1 ex-
pression in iWAT was associated with induction of browning,
brown fat gene programs, and PGC1a and UCP1 protein
levels (Figures 3E–3H). The delivery of shHSF1 and HSF1 adeno-
viruses appeared to be specific to iWAT, given that HSF1
levels were modulated only in this depot (Figures S3A and, October 6, 2015 ª2015 Elsevier Inc. 697
Figure 2. HSF1 Null Mice Have Impaired Energy Metabolism
(A–H) Analysis of 2-month-old WT and HSF1 null (HSF1 KO) mice.
(A) Weights of brown (BAT), inguinal (iWAT), epididymal (eWAT), mesenteric (mWAT), and retroperitoneal (rWAT) fat pads.
(B) Representative H&E staining of BAT and iWAT.
(C) Gene expression analysis of brown fat markers in BAT and iWAT.
(D and E) Representative UCP1 staining and UCP1 protein levels in iWAT.
(F) Oxygen consumption levels. ANCOVA analysis using body weight and genotype as covariance shows significant decrease in oxygen consumption in HSF1
null mice (p = 0.018 at room temperature and 0.046 at thermoneutrality, n = 4).
(G) Core temperatures during cold exposure.
(H) PGC1a and UCP1 levels in BAT and iWAT obtained from mice at room temperature (RT) or after 6 hr of cold exposure (4C). Annotation indicates significant
effect of a, genotype; b, temperature; or c, significant temperature-genotype interaction using two-way ANOVA analysis.
(I) Oxygen consumption rate (OCR) in differentiated primary SVF cells from BAT and iWAT of 2-month-old WT and HSF1 null mice in basal conditions, in the
presence of 1 mM oligomycin, 1 mM FCCP, or 0.5 mM Antimycin A. DOCR is calculated by subtracting OCR measured after antimycin addition from basal OCR,
from OCR after oligomycin addition, or from OCR after FCCP addition.
n = 6 per group unless stated otherwise. Data are presented as mean ± SEM and *p < 0.05, **p < 0.01 compared to control group.
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Figure 3. Modulation of HSF1 Levels in iWAT Affects Browning through PGC1a
(A) Schematic representation of the experimental design through (B)–(D).
(B–D) (B) Representative H&E andUCP1 staining; (C) mRNA levels of thermogenic and brown fat genes; and (D) protein levels of HSF1, PGC1a, and UCP1 in iWAT
of 2-month-old mice injected with control (Ad-Con) or shHSF1 (Ad-shHSF1) adenovirus in iWAT depots.
(E) Schematic representation of the experimental design through (F)–(H).
(F)–(H) (F) Representative H&E and UCP1 staining; (G) mRNA levels of thermogenic and brown fat genes; and (H) protein levels of HSF1, PGC1a, and UCP1 in
iWAT of 4-month-old mice injected with adenovirus expressing either control (Ad-Con) or HSF1 (Ad-HSF1).
(I) Illustration of the experimental design for the delivery of control or HSF1 adenoviruses into the iWAT of 4-month-old WT or PGC1a null (PGC1a KO) mice.
(J) mRNA levels of HSF1 and brown fat genes in iWAT obtained from WT and PGC1a null mice injected with control (Ad-Con) or HSF1 (Ad-HSF1) adenovirus.
(K) Core temperatures ofWT and PGC1a null mice injectedwith control (Ad-Con) or HSF1 (Ad-HSF1) adenovirus during 3 hr of cold exposure. AUC (area under the
curve) and annotation indicates significant effect of a, genotype; b, injection; or c, significant injection-genotype interaction using two-way ANOVA analysis.
n = 6 per group. Data are presented as mean ± SEM and *p < 0.05, **p < 0.01 compared to control group.S3B). Overall these data further support a fat-cell-autonomous
function of HSF1.
Given HSF1’s ability to induce PGC1a and its downstream
mitochondrial, brown fat, and energy utilization genes in vitro
and in vivo (Figures 1–3), we next examined the requirement of
PGC1a for HSF1-mediated regulation of these gene programs.
As shown in Figures 3I–3K, ectopic expression of HSF1 in iWAT
was associatedwith increased levels ofmitochondrial and brownCellfat gene expression and improved cold tolerance inWT, but not in
PGC1a KO mice. These results demonstrate that PGC1a is
necessary for HSF1’s metabolic action in inguinal fat tissues.
Celastrol Elicits Metabolic Effects through HSF1 and
PGC1a
Having established the existence of the HSF1-PGC1a axis, we
next tested whether pharmacological activation of this axisMetabolism 22, 695–708, October 6, 2015 ª2015 Elsevier Inc. 699
Figure 4. The HSF1 Activator Celastrol
Elicits Metabolic Effects through HSF1 and
PGC1a
(A and B) Gene expression analysis of mitochon-
drial and brown fat gene programs in differentiated
primary cells (SVF) obtained fromBAT and iWAT of
2-month-old WT, HSF1 null (HSF1 KO), or PGC1a
null (PGC1a KO) mice, after treatment with vehicle
or celastrol (CEL).
(C) mRNA levels of brown fat genes in inguinal
fat tissue (iWAT) obtained from mice injected
with either control (Ad-Con), shHSF1 (Ad-
shHSF1), or shPGC1a (Ad-shPGC1a) adenovi-
ruses and treated with or without CEL for 3 days.
n = 6 per group. Data are presented as mean ±
SEMand *p < 0.05, **p < 0.01, compared to control
group.in vivo would lead to enhanced brown fat functions. We chose to
treat mice with the HSF1 activator celastrol, due to the clear
in vitro effects of this compound on HSF1 and PGC1a (Figures
1A and 1C–1F), because of celastrol’s known favorable safety
profile in mice (Kiaei et al., 2005; Yang et al., 2006; Paris et al.,
2010) and since our data suggested it has potent effects on pri-
mary human cells (Figure S1N). We first determined the speci-
ficity of celastrol’s function and the genetic requirement of
HSF1 and PGC1a for the celastrol-mediated activation of meta-
bolic target genes. As shown in Figures 4A and 4B, the induction
of thermogenic and mitochondrial gene programs elicited by ce-
lastrol in WT cells was markedly blunted in cells derived from
either HSF1 or PGC1a null mice. To further determine whether
the effects of celastrol were fat-cell-autonomous and dependent700 Cell Metabolism 22, 695–708, October 6, 2015 ª2015 Elsevier Inc.in vivo on the HSF1-PGC1a axis, we
measured celastrol-mediated activation
of metabolic genes in mice with HSF1 or
PGC1a depletion selectively in iWAT
and showed attenuated induction ofmito-
chondrial, brown fat, and fatty acid utiliza-
tion genes in response to treatment in the
absence of either HSF1 or PGC1a (Fig-
ure 4C). Together, these data demon-
strate that celastrol activates mitochon-
drial and thermogenic gene programs
specifically through HSF1 and PGC1a.
HSF1 Activation by Celastrol
Increases Energy Expenditure
Having demonstrated the specificity of
the HSF1’s activator celastrol, we next
tested whether treatment of mice with
this compound would lead to reprog-
ramming of metabolic signatures in fat
and other tissues. As shown in Fig-
ure 5A, the levels of PGC1a and of
genes involved in brown fat and mito-
chondrial function, thermogenesis and
lipid oxidation were increased in brown
fat tissues of celastrol-treated mice,
with no concomitant increase in adipo-genic gene programs (Figure S4A). In addition, transmission
electron microscopy (TEM) examination of BAT sampled
from celastrol-treated animals showed increased mitochon-
drial number, as well as better preservation of mitochondrial
cristae structure (Figure 5B), and molecular analysis demon-
strated induction of classic markers of brown fat cells and
beige cells (Figure 5C), increased UCP1 levels, and staining
in iWAT (Figures 5D and 5E), with no effects on adipogenic
gene programs (Figure S4A). Consistent with these molecular
changes, celastrol-treated mice exhibited improved cold toler-
ance (Figure 5F). A similar induction of thermogenic and mito-
chondrial gene expression profiles (Figures S4B and S4C) and
effects on browning (Figures S4D and S4E) were also
observed in mice on chow diet treated with celastrol.
Figure 5. HSF1 Activation by Celastrol Induces Mitochondrial, Brown, and Beige Fat Programs in Adipose Tissues and Increases Energy
Expenditure
(A–G) Analysis of mice on HFD, untreated (HFD, n = 6), or treated with celastrol at 1 mg/kg/day (HFD + CEL1, n = 6) or 3 mg/kg/day (HFD + CEL3, n = 7).
(A) Gene expression levels of brown fat programs in BAT.
(B) Representative transmission electron microscopy images (TEM) and quantification of mitochondrial area in BAT.
(C) Gene expression analysis of brown and beige selective genes in iWAT.
(D and E) Representative UCP1 staining and UCP1 protein levels of iWAT.
(F) Core body temperatures during cold exposure.
(G) Oxygen consumption levels and (H) PGC1a and UCP1 levels in BAT and iWAT in mice treated with or without CEL for 3 days at room temperature (RT) or at
thermoneutrality (30C). n = 6.
(I) Oxygen consumption rate in differentiated 10T1/2 cells expressing control or siHSF1 in the presence of vehicle or 0.5 mMCEL for 72 hr, in basal conditions, or
with 0.5 mM oligomycin, 1 mM FCCP, or 0.5 mM antimycin A. DOCR is calculated by subtracting OCR measured after antimycin addition from basal OCR, from
OCR after oligomycin addition, or from OCR after FCCP addition.
Data are presented as mean ± SEM and *p < 0.05, **p < 0.01 compared to control group.
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Figure 6. HSF1 Regulates Mitochondrial Function in Muscle
(A) Expression levels of PGC1a and of its downstream mitochondrial genes in the gastrocnemius of control and celastrol-treated mice (HFD, n = 6; HFD + CEL1,
n = 6; HFD + CEL3, n = 7).
(B) Representative TEM image of red and white gastrocnemius muscle and quantification of mitochondrial areas.
(C) Exercise tolerance and food intake in mice treated with or without CEL for 10 days (n = 4).
(D) Expression of fiber type genes in the gastrocnemius muscle of 2-month-old WT and HSF1 KO mice (n = 6).
(E and F) SDH staining and treadmill performance of 2-month-old WT and HSF1 KO mice (n = 4).
(G) mRNA levels of HSF1, PGC1a, and mitochondrial genes in gastrocnemius muscle of 2-month-old WT and PGC1a KO mice injected with control (Ad-Con) or
HSF1 (Ad-HSF1) adenovirus unilaterally into the contralateral lower limbs (n = 4 per group).
Data are presented as mean ± SEM and *p < 0.05, **p < 0.01 compared to control group.We next determined the effects of pharmacological activation
of HSF1 on energy expenditure and showed that administration
of celastrol to mice housed at either room temperature or
at thermoneutrality was associated with increased oxygen
consumption and with elevation of brown fat gene expression
programs in BAT and iWAT (Figures 5G and 5H), with no
concomitant changes in food intake nor in locomotor activity
(Figures S4F and S4G). The effects on oxygen consumption
were recapitulated in vitro and abolished in HSF1-depleted cells,
demonstrating that celastrol affects energy expenditure in a
HSF1-dependent manner (Figure 5I).
Celastrol Increases Mitochondrial Function in Muscle
To determine whether the HSF1-PGC1a axis was also activated
in other metabolic tissues in addition to fat, we analyzed the
levels of PGC1a and its target genes in muscle, brain, kidney,
and liver of celastrol-treatedmice and inmicewith HSF1 ablation
(Figures S5A and S5B). This survey revealed that the transcrip-702 Cell Metabolism 22, 695–708, October 6, 2015 ª2015 Elsevier Intional program downstream of PGC1a is activated also in skel-
etal muscle. Furthermore, we examined the expression of hypo-
thalamic genes regulating energy balance previously reported to
be altered in mice with neuronal specific knockout of PGC1a (Ma
et al., 2010) and showed no changes in their expression levels in
treated mice (Figure S5C).
Since it has been shown that PGC1a function in muscle con-
tributes to energy expenditure (Handschin and Spiegelman,
2006; Lagouge et al., 2006), we further analyzed the effects of
HSF1 activation on PGC1a and on its targets in mice treated
with celastrol during HFD and demonstrated increased expres-
sion of mitochondrial and fiber-type genes (Figure 6A), reduced
ectopic fat deposition (Figure 6B), and increased mitochondrial
number in the gastrocnemius of celastrol-treated mice (Fig-
ure 6B). Given that modulation of PGC1a levels in muscle has
been shown to affect exercise tolerance (Handschin et al.,
2007), we tested the effects of celastrol treatment on muscle
endurance. Our analysis revealed that treated mice hadc.
increased ability to run longer, to cover a larger distance, and to
generate higher average work compared to controls (Figure 6C),
consistent with an overall increase in muscle endurance.
Conversely,micewith ablationofHSF1showed reducedoxida-
tive fibers in their gastrocnemius (Figures6Dand6E) and impaired
muscleendurance (Figure6F). Furthermore,HSF1gainof function
inmusclewasassociatedwith increased expressionofmitochon-
drial genes in WT but not in PGC1a KOmice, suggesting that the
effects ofHSF1onmuscle physiology arePGC1adependent (Fig-
ure 6G). Overall, these data suggest a role of the HSF1-PGC1a
axis also in modulating muscle physiology.
Celastrol Protects against Obesity, Insulin Resistance,
and Hepatic Steatosis through HSF1 Activation
To further examine the physiological implications of the meta-
bolic reprogramming induced by celastrol, we assessedwhether
HSF1 pharmacological activation would prevent obesity. As
shown in Figure 7A, celastrol treatment throughout the HFD
regimen protected mice from weight gain, without affecting
their food intake, locomotor activity, or respiratory exchange
ratio (Figure S6A). Examination of body composition by NMR
spectroscopy revealed a marked and selective decrease in fat
mass in celastrol-treated mice (Figures 7B and S6B). Consistent
with this reduction, we observed decreased adipose depots
exhibiting smaller adipocytes and reduced lipid accumulation
(Figures 7C and 7D), an improvement in metabolic parameters
(Figures 7E and S6B), and enhanced insulin sensitivity (Figures
7F) in the celastrol-treated group. Reductions in the liver enzyme
alanine transaminase (ALT) and in the levels of the proinflamma-
tory cytokine TNFa were also observed in the treated group
(Figure S6C). Further evidence of improved metabolic profiles
in celastrol-treated mice was the decrease in liver weights due
to reduced hepatic steatosis and intrahepatic triglycerides accu-
mulation (Figures 7G–7I). Interestingly, celastrol treatment of
mice on regular chow diet also was associated with a reduction
in adipose depots, but not with body weight changes (Figures
S6D and S6E). To further ensure that the effects of celastrol on
body weight were not related to compound toxicity, we moni-
tored a number of parameters from the beginning of the treat-
ment over a 2 week period. As shown in Figures S6F–S6J, while
celastrol-treated mice showed decreased body weight and
increased oxygen consumption compared to control mice,
they had similar food intake and locomotor activity. Blinded anal-
ysis of H&E-stained histological tissue sections revealed no
apparent pathology (Figure S6K), and serum chemistry analysis
demonstrated the absence of any readily apparent drug toxicity
(Table S1). As further evidence of the specificity of the compound
and the genetic requirement of HSF1, celastrol treatment in
HSF1 null mice had no effects on body weight, metabolic param-
eters, cold tolerance, or brown fat gene programs in BAT or iWAT
(Figures 7J and S6L). Overall, these data demonstrate that
pharmacological activation of HSF1 protects from diet-induced
obesity and improves metabolic parameters in mice.
DISCUSSION
We have uncovered a critical role for HSF1 as a transcriptional
regulator of brown fat, beige fat, and muscle physiology. HSF1
has been traditionally characterized as an ancient, conserved fac-Celltor protecting cells against protein misfolding and aggregation
induced by heat shock and shown to increase longevity in
C. elegans by promoting protein homeostasis (Morley and Mori-
moto, 2004). Recently, HSF1 has been tied to negative outcomes
in tumors by mediating the emergence of a stress-resistant
phenotype in malignant cancers through activation of transcrip-
tional programs principally involved in protein folding, mitosis,
and translation (Mendillo et al., 2012). Our findings suggest that
the role ofHSF1mayneed tobeextendedbeyond itswell-charac-
terized role in chaperoneprotein regulation. The unsuspectedand
surprising role of HSF1 reported here suggests fundamental
differences from that exerted in response to hyperthermia and in
tumor cells, in that it directly drives the transcriptional activation
of PGC1a-mediated gene programs required for adaptive energy
metabolism.While our results show that HSF1-mediated ‘‘brown-
ing’’ of subcutaneous white fat tissue requires PGC1a, we cannot
rule out that HSF1 may also exert its function through other regu-
lators of beige fat tissue biology, such as via the transcriptional
cofactor PRDM16 (Cohen et al., 2014), to orchestrate an inducible
response to cold exposure. This possibility is consistent with our
data showing HSF1-mediated PRDM16 mRNA regulation, both
in isolated cells and in mouse tissues. A systematic genome-
wide analysis of HSF1-activated transcriptional programs in fat
tissues should provide further insights on the scope and scale of
HSF1’s role in brown and beige fat biology. Furthermore, our
observation that HSF1 activation also elevated mitochondrial
number and function in skeletal muscle suggests that the overall
increased energy expenditure observed in celastrol-treated
mice results from alterations in at least two distinct metabolically
active tissues.Futureanalysisof the responseofUCP1KOmice to
celastrol and of the extent of shivering of treated mice will help
clarify the relative contribution of fat versus skeletal muscle in
the HSF1-mediated metabolic effects elicited by celastrol.
The HSF1-regulated thermogenic gene program in white fat
tissue can be recapitulated in isolated cells and appears to be
sufficient to affect cellular respiration. Nonetheless, the pres-
ence of UCP1 does not always correlate with uncoupling activity;
as such, further detailed analysis of this process in response to
stimuli such as norepinephrine should provide a more detailed
understanding of how HSF1 regulates thermogenic functions in
brown and beige cells (Li et al., 2014). It has been recently shown
that fat cells can sense cool temperatures directly, indepen-
dently of the involvement of the canonical cAMP pathway or
the TRPV family of thermosensors (Ye et al., 2013). Although it
cannot be excluded that activation of the sympathetic nervous
system during cold exposure may lead to activation of HSF1 in
peripheral tissues, our data raise the possibility for a role of
HSF1 in cold sensing and in switching on an intrinsic-thermo-
genic program in cells, suggesting a potential function of HSF1
as a stress response protein that may confer an ‘‘innate’’ ability
of subcutaneous fat cells to initiate heat generation. Of note,
the mechanisms for the activation of HSF1 via cold exposure
are distinct from those elicited by hyperthermia and do not
involve the hyperphosphorylation characteristic of heat-acti-
vated HSF1 (Cullen and Sarge, 1997). Whether cold stimuli
induce distinct posttranslational modifications on HSF1 to affect
its multimerization, changing its promoter binding patterns to
include noncanonical bindingmotifs, and confer new gene target
specificity needs to be further investigated.Metabolism 22, 695–708, October 6, 2015 ª2015 Elsevier Inc. 703
(legend on next page)
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Our data suggest that pharmacological activation of theHSF1-
PGC1a axis with celastrol ameliorates metabolic dysfunction. Of
note, celastrol has been known for its antioxidative and anti-in-
flammatory properties (Salminen et al., 2010), and reported to
cross the brain-blood barrier (Kiaei et al., 2005). Although our
analysis did not reveal any significant changes in the levels of
mitochondrial genes in the brain of treated mice, it remains to
be assessed whether the beneficial effects of celastrol for the
treatment of obesity are due to activation of the sympathetic ner-
vous system in addition to its intrinsic effects on fat and muscle
reported here.
Overall our study provides a proof of principle that pharmaco-
logical activation of HSF1 promotes thermogenic and mitochon-
drial gene programs in brown and beige cells and in skeletal
muscle, with profound impact on metabolic parameters. The
beneficial effects of HSF1 activation by celastrol observed in
an animal model of diet-induced obesity included decreased
adipose tissue expansion in response to HFD regimens and
concomitant relief from the associated comorbidities, including
improvement in insulin sensitivity and decreased hepatic steato-
sis. It is worth noting that, to date, pharmacological treatments
such as those employing agonists for the b3-adrenergic receptor
and for PPARg have had little clinical success due either to their
limited effects in enhancing energy expenditure (Cypess and
Kahn, 2010; Cypess et al., 2012) or to dose-limiting adverse
events (Boss and Farmer, 2012). In contrast, our data suggest
that pharmacological activation of the HSF1-PGC1a axis may
represent a possible strategy to ameliorate a wide range of pa-
thologies associated with altered metabolic conditions.
While this paper was in revision, another report was published
indicating that celastrol can act as a leptin sensitizer to coun-
teract obesity (Liu et al., 2015). While both studies highlight the
beneficial effects of celastrol in treating obesity, the two reports
differ in the proposed mechanisms of celastrol’s action. Specif-
ically, the other recent report focused on celastrol’s central ef-
fects on decreasing weight by affecting food intake, while our
paper emphasizes celastrol peripheral action through activation
of a transcriptional axis involvingHSF1andPGC1a. Thecontrast-
ingmechanismsdescribed in these two reportsmay reflect differ-
ences in the sensitivities of different tissues for different dosages
of celastrol. This conclusion is bolstered by the fact that our anal-
ysis, using 3-fold fewer amounts of celastrol than recently
described, did not uncover any effects on food intake. It should
be noted that the two studies also differed on the models of
obesity analyzed. Our studies involved normal mice fed a HFD,
a condition in which celastrol was protective. In contrast, the
other manuscript analyzed the effects of celastrol on obese and
leptin-resistant mice. Interestingly, while the recent study pri-
marily focused on celastrol effects on food intake, in their anal-
ysis they did observe that in pair-feeding experiments celastrolFigure 7. HSF1 Activation Protects Mice from High-Fat-Diet-Induced O
(A–I) Analysis of mice on HFD, either without (HFD, n = 6) or treated with celastrol a
including: (A) body weights; (B) fat mass; (C) weights of brown (BAT), inguinal (i
depots; (D) representative H&E staining of fat depots; (E) serumparameters; (F) GT
(I) intrahepatic triglyceride levels (TAG).
(J) Comparison between the response to CEL in 2-month-old WT and HSF1 KO m
per group), including body weights, insulin sensitivity measured by GTT (AUC) an
AUC, area under the curve. Data are presented as mean ± SEM and *p < 0.05, *
Cellincreased energy expenditure. Such results are consistent with
our observations presented here. Further studies should help
clarify whether central or peripheral effects of celastrol predomi-
nate at clinically relevant concentrations of the drug.
EXPERIMENTAL PROCEDURES
Cell Culture
10T1/2 cells (ATCC) and primary fat SVF cells were used in this study. A total of
90% confluent 10T1/2 cells were immediately transferred to a water bath
placed inside a CO2 incubator set at 37
C or 31C for the indicated time. For
heat shock experiments, 10T1/2 cells were exposed at 42C for 1 hr. For cool-
ing experiments, 10T1/2 cells were transfected with siRNA, and 48 hr later
medium was changed with culture medium prewarmed at 37C or 31C and
immediately transferred to a water bath placed inside a CO2 incubator set at
37C or 31C for the indicated time. For the analysis of the effects of celastrol
on gene expression of differentiated cells, 10T1/2 cells were treated with
celastrol for 24 hr after 7 days of differentiation. The analysis of the effects of
HSF1 knockdown was performed in 10T1/2 cells transfected with control or
siHSF1 and differentiated for 4 days prior to treatment with 0.5 mM celastrol
for 24 hr. To obtain WT, HSF1 null and PGC1a null mouse SVF, BAT, and
iWAT were obtained fromWT and null mice, minced, and subjected to collage-
nase (1 mg/ml) digestion at 37C for 45 min in buffer containing 0.123 M NaCl,
5 mM KCl, 1.3 mM CaCl2, 5 mM glucose, 100 mM HEPES, and 4% BSA;
filtered through a 100 um nylon screen; and centrifuged at 150 g for 5 min at
room temperature. Cell pellets were washed twice and resuspended in
DMEM medium containing 25 mM glucose, 20% FBS, 20 mM HEPES, and
1% pen/strep, and culture medium was changed daily. The differentiation
process for 10T1/2 and SVF was described in Supplemental Experimental
Procedures.
Cellular Metabolic Rates
Cellular metabolic rates were measured using a XF24 Analyzer (Seahorse
Bioscience). 10T1/2 cells were transfected with control or si-HSF1 and differ-
entiated for 5 days and/or treated with vehicle or celastrol for 72 hr. BAT and
iWAT SVF cells from WT and HSF1 null mice were differentiated for 8 days.
Respiration was measured under basal conditions, following the addition of
ATP synthase inhibitor oligomycin, the mitochondrial uncoupler FCCP, or
the complex III inhibitor antimycin A. The calculation methods can be found
in Supplemental Experimental Procedures.
Transfections and Luciferase Assays
10T1/2 cells were transfected with Xtreme HP (Roche) or Nucleofector 96-well
system (Amaxa). Gene expression analysis was performed 48 hr after transfec-
tion. Luciferase activity was assayed 24 hr after transfection with dual lucif-
erase system (Promega). The PGC1a-luciferase reporter was purchased
from Addgene. A deletion mutant of the PGC1a-luciferase reporter at the
HSE putative sequence was generated with QuikChange II Site-Directed
Mutagenesis Kit (Agilent), using the following primers: F, 50-ATGTGCTGGGT
TAGTTTTTTTAAAGTAGAATTAG-30, and R, 50-CTAATTCTACTTTAAAAAAAA
CTAACCCAGCACAT-30.
Real-Time PCR
Total RNAwas extracted from cultured cells or tissues with TRIzol (Invitrogen),
and 1 mg total RNA was reverse transcribed to cDNA with First-Strand cDNA
Synthesis Kit (Roche), according to the manufacturers’ instructions. Quantita-
tive real-time PCR was performed with the ABI PRISM 7900HT sequencebesity, Insulin Resistance, and Hepatic Steatosis
t doses of 1 mg/kg/day (HFD+CEL1, n = 6) or 3 mg/kg/day (HFD + CEL3, n = 7),
WAT), epididymal (eWAT), mesenteric (mWAT), and retroperitoneal (rWAT) fat
T and ITT assays; (G) liver weights; (H) representative H&E staining of livers; and
ice on HFD supplemented with or without 3 mg/kg/day CEL for 4 weeks (n = 4
d ITT (AUC), liver weights, and core temperatures during 4 hr of cold exposure.
*p < 0.01 compared to control group.
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detection system (ABI) using SYBR green (Roche). The details can be found in
Supplemental Experimental Procedures.
Coimmunoprecipitation Assay and Protein Analysis
Coimmunoprecipitation was performed with the Catch and Release v2.0
Reversible Immunoprecipitation System (Millipore). Proteins were separated
by 10% Bis-Tris Gel (Invitrogen), transferred to PVDF membranes (Pierce),
and incubated with anti-PGC1a (Santa Cruz, sc-13067) or anti-HSF1 (Abgent,
AJ1374a) antibodies overnight at 4C and at room temperature for 1 hr with
secondary antibodies. Immune complexes were visualized by using SuperSig-
nal West Dura Extended Duration Substrate (Pierce), following the manufac-
turer’s instructions. For measuring UCP1 protein levels in tissues with western
blot analysis, proteins were extracted with RIPA buffer consisting of 20 mM
Tris, 150 mM NaCl, 1% Triton X-100, and protease inhibitors (Roche), and
15 mg proteins were loaded on a 10% Bis-Tris Gel and transferred to PVDF
membranes (Pierce) and incubated with anti-UCP1 (Abcam, ab10983) and
anti-b-actin (Sigma, A5316) antibodies.
Chromatin Immunoprecipitation Assays
ChIP assays were performed using a ChIP assay kit (Millipore), according to
manufacturer’s instructions and as previous reported (Ma et al., 2014); details
can be found in Supplemental Experimental Procedures.
Animal Studies
Mouse studies were performed according to guidelines of the National Insti-
tute of Diabetes and Digestive and Kidney Diseases Animal Care and Use
Committee. C57BL/6J, HSF1 heterozygous mice (Balb/C) were purchased
from The Jackson Laboratory. PGC1a heterozygous mice were a kind gift
of Bruce M. Spiegelman (Harvard Medical School, Boston, MA, USA). Het-
erozygous mice were crossed to obtain WT and knockout genotypes. Male
mice were used for all the experiments described in this study. For treat-
ments, celastrol was mixed with powdered chow (NIH 07) or with HFD
chow (60%, ResearchDiet, D12492). For assessing metabolic parameters,
2-month-old mice were fed either chow diet or HFD with or without celastrol
for 3 weeks and 8 weeks. Body composition was measured using NMR
(Echo Medical Systems). To monitor the effects of celastrol treatment,
2-month-old mice were fed HFD with or without celastrol for 2 weeks, and
body weights, oxygen consumption, food intake and locomotor activity
were measured every 2 days throughout the experiments with CLAMS (Co-
lumbus Instruments, Columbus, OH, USA). To measure the metabolic effects
of celastrol on WT and HSF1 KO mice, 2-month-old mice were fed a HFD,
with or without celastrol, for 4 weeks, and parameters such as body weight,
insulin sensitivity, liver weights, and cold tolerance were measured at the end
of the treatment. The details for cold exposure, treadmill exercise, energy
expenditure, and GTT and ITT analysis can be found in Supplemental Exper-
imental Procedures.
Adenoviral Delivery in Inguinal Fat and Muscle
Adenoviruses expressing control (CMV-GFP), mouse HSF1 (HSF1-CMV-
GFP), control shRNA (U6-shRNA-CMV-GFP), shHSF1 (U6-shHSF1-CMV-
GFP), and shPGC1a (U6-shPGC1a-CMV-GFP) were constructed, amplified,
and purified by Vector Biolabs. A total of 50 ml of 5 3 109 Pfu of each
adenovirus diluted in saline was injected bilaterally (s.c.) into the inguinal fat
pads of mice (Ma et al., 2014). For intramuscular delivery of adenovirus,
10 ml of 2 3 1010 Pfu control or mouse HSF1 adenovirus diluted in saline
was injected unilaterally into the contralateral lower limbs of mice (Ruas
et al., 2012). Mice were either sacrificed at the fourth day after viral delivery
or were celastrol treated as noted, and tissues were dissected for further
analysis or monitored for changes in body temperature under cold environ-
ment for 3 hr.
Serum Parameters and Liver Triglyceride Level Determination
Serum leptin and insulin levels were measured with RIA kits (Millipore); blood
glucose levels were measured with an automated reader (Bayer); triglyceride
(Thermo), cholesterol (Sigma), HDL (Sigma), LDL/VLDL (Sigma), and ALT
(Sigma) levels were assayed by colorimetric tests; and serum TNFa (R&D)
and IFNg (Phoenix Pharmaceuticals) were determined by ELISA. Analysis of
serum chemistry including levels of serum minerals, lipids, and renal and liver706 Cell Metabolism 22, 695–708, October 6, 2015 ª2015 Elsevier Inenzymes was performed by the Department of Laboratory Medicine at the NIH
Clinical Center. Lipids were extracted from liver samples, and triglyceride
levels were determined by triglyceride reagent (Sigma). The details can be
found in Supplemental Experimental Procedures.
Histological Analysis
Dissected tissues were fixed in 10% neutral buffered formalin and embedded
in paraffin according to standard procedures. Tissue sections of 5 mm thick-
ness were stained with H&E (Histoserv) or with UCP1 antibody (Abcam,
ab10983), following the manufacturer’s instructions (Vector labs). Frozen sec-
tions of gastrocnemiusmuscle fromWT andHSF1 KOmicewere prepared and
stained with succinic dehydrogenase (SDH). Transmission electron micro-
scopy (TEM) analysis was performed by EM Facility, National Cancer Institute,
at Frederick, MD, USA. The details can be found in Supplemental Experimental
Procedures.
Human Adipose Tissue
Fat biopsies of subcutaneous abdominal region were obtained from three
obese women (BMI >40) recruited at the NIH. The study was approved by the
NIDDK Institutional Review Board (clinicaltrials.gov identifier NCT00428987).
All subjectsgavewritten informedconsent.SVFcells fromhumansubcutaneous
fat tissue were obtained, differentiated, and treated with DMSO or celastrol at
the concentrations indicated for 24 hr. The details can be found in Supplemental
Experimental Procedures.
Statistical Analysis
Student’s t test was used for comparison between two groups. One-way
ANOVA followed by the Dunnett post hoc test was used for multiple compar-
isons versus the control group (GraphPad Software). Two-way ANOVA was
used to examine interactions between variables and ANCOVA was used to
analyze oxygen consumption data of WT and HSF1 null mice by SPSS soft-
ware (Tscho¨p et al., 2011). p < 0.05 was considered as statistically significant.
Results are shown as mean ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, and Supplemental
Experimental Procedures and can be found with this article at http://dx.doi.
org/10.1016/j.cmet.2015.08.005.
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